Literature DB >> 10754493

Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes.

T Kageshita1, C V Hamby, S Hirai, T Kimura, T Ono, S Ferrone.   

Abstract

Despite its potential clinical relevance, alpha(v)beta(3) expression has been analyzed only in a limited number of melanoma lesions, mostly nodular melanoma (NM) and superficial spreading melanoma (SSM). Therefore, in the present study, we have correlated alpha(v)beta(3) expression in 33 acral lentiginous melanomas (ALMs), 6 lentigo maligna melanomas, 7 mucosal melanomas, 12 NMs and 9 SSMs with their antigenic profile, with their histo-pathological characteristics and with the clinical course of the disease. Furthermore, we have compared alpha(v)beta(3) expression in ALM lesions with that in NM and SSM lesions since this information helps to clarify the relationship of the latter 2 histotypes with ALM. Such a relationship is uncertain since ALM has a clinical course similar to that of NM and SSM despite different antigenic profiles and biological characteristics. The level of alpha(v)beta(3) expression in primary lesions was not correlated with that of high-m. w. melanoma-associated antigen and intercellular adhesion molecule-1, with lesion thickness and with disease recurrence in ALM but was significantly correlated with these 4 parameters in the other melanoma histotypes analyzed. Therefore, alpha(v)beta(3) expression appears to have a differential clinical significance in ALM and in the other histotypes of melanoma we have analyzed since it appears to play a significant role in the progression of the disease only in non-ALM histotypes. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754493     DOI: 10.1002/(sici)1097-0215(20000320)89:2<153::aid-ijc9>3.0.co;2-1

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Authors:  Kevin B Kim; Victor Prieto; Richard W Joseph; Abdul H Diwan; Gary E Gallick; Nicholas E Papadopoulos; Agop Y Bedikian; Luis H Camacho; Patrick Hwu; Chaan S Ng; Wei Wei; Marcella M Johnson; Sabine M Wittemer; Anna Vardeleon; Aaron Reckeweg; A Dimitrios Colevas
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

2.  Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons.

Authors:  Dipanjan Pan; Manojit Pramanik; Angana Senpan; John S Allen; Huiying Zhang; Samuel A Wickline; Lihong V Wang; Gregory M Lanza
Journal:  FASEB J       Date:  2010-11-19       Impact factor: 5.191

3.  Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.

Authors:  Jingquan Jia; Alex Starodub; Ian Cushman; Yingmiao Liu; Deborah J Marshall; Herbert I Hurwitz; Andrew B Nixon
Journal:  Anticancer Drugs       Date:  2013-03       Impact factor: 2.248

Review 4.  Nanomedicine strategies for molecular targets with MRI and optical imaging.

Authors:  Dipanjan Pan; Shelton D Caruthers; Junjie Chen; Patrick M Winter; Angana SenPan; Anne H Schmieder; Samuel A Wickline; Gregory M Lanza
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

5.  MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model.

Authors:  Kent S Boles; Anne H Schmieder; Alexander W Koch; Richard A D Carano; Yan Wu; Shelton D Caruthers; Raymond K Tong; Scott Stawicki; Grace Hu; Michael J Scott; Huiying Zhang; Benton A Reynolds; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2010-06-28       Impact factor: 5.191

Review 6.  Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions.

Authors:  G M Lanza; P M Winter; S D Caruthers; M S Hughes; Grace Hu; A H Schmieder; S A Wickline
Journal:  Angiogenesis       Date:  2010-04-22       Impact factor: 9.596

7.  CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.

Authors:  Qiming Chen; Carol D Manning; Hillary Millar; Francis L McCabe; Catherine Ferrante; Celia Sharp; Lillian Shahied-Arruda; Parul Doshi; Marian T Nakada; G Mark Anderson
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

8.  Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Authors:  Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-03-24       Impact factor: 5.191

Review 9.  A brief account of nanoparticle contrast agents for photoacoustic imaging.

Authors:  Dipanjan Pan; Benjamin Kim; Lihong V Wang; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-08-23

10.  High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model.

Authors:  Michal Lijowski; Shelton Caruthers; Grace Hu; Huiying Zhang; Michael J Scott; Todd Williams; Todd Erpelding; Anne H Schmieder; Garry Kiefer; Gyongyi Gulyas; Phillip S Athey; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  Invest Radiol       Date:  2009-01       Impact factor: 6.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.